Top Abstract Purchase Related
Home
>
Node
>
Subnode

The content of a heparin-like anticoagulant in the flowers of the meadowsweet (Filipendula ulmaria)

Kudriashov, B.A.; Liapina, L.A.; Azieva, L.D.

Farmakologiia i Toksikologiia 53(4): 39-41

1990

ISSN/ISBN: 0014-8318
PMID: 2226759
Document Number: 354223
The flowers of Filipendula ulmaria were found to contain heparin bound to the plant proteins in the form of a complex. This complex enhances the anticoagulant and fibrinolytic properties of the nonenzymatic nature at its administration to animals both intramuscularly and intravenously. The neutralizing effect of protaminesulphate on the anticoagulant activity of the plant heparin was shown. The identity of the action on the hemostasis system of heparin of animal and plant origin was found.

Document emailed within 1 workday
Secure & encrypted payments

Peresun'ko, A.P.; Bespalov, V.G.; Limarenko, A.I.; Aleksandrov, V.A. 1993: Clinico-experimental study of using plant preparations from the flowers of Filipendula ulmaria (L.) Maxim for the treatment of precancerous changes and prevention of uterine cervical cancer Voprosy Onkologii 39(7-12): 291-295
Byshevskiĭ, A.S.; Sokolovskiĭ, S.R. 1982: Potentiation of the anticoagulant effects of a phosphatidylserine-containing anticoagulant and heparin Voprosy Meditsinskoi Khimii 28(2): 30-34
Ielciu, I.; Hanganu, D.; Păltinean, R.; Vlase, L.; Frédérich, M.; Gheldiu, A.-M.; Benedec, D.; Crişan, G. 2018: Antioxidant capacity and polyphenolic content of the Echinocystis lobata (Michx.) Torr. et A.Gray flowers Pakistan Journal of Pharmaceutical Sciences 31(2 Suppl.): 677-683
Dalmora, S.L.; Assaf, G.S.; Dalmora, M.E.; Vaucher, L.C.; Vaccari, S.F. 1991: Determination of anticoagulant activity of heparin Revista do Hospital das Clinicas 46(2): 59-62
Bychko, S.M.; Kharlamova, V.N. 1975: The anticoagulant properties of different heparin fractions Biulleten' Eksperimental'noi Biologii i Meditsiny 79(2): 61-63
Bremmelgaard, A. 1986: Heparin and monitoring of peroral anticoagulant therapy Ugeskrift for Laeger 148(21): 1275-1276
Ofosu, F.A. 1988: Mechanisms for the anticoagulant effect of heparin and related polysaccharides Nouvelle Revue Francaise d'Hematologie 30(3): 155-160
Krupiński, K.; Bielawiec, M.; Breddin, H.K. 1994: Antithrombotic properties of heparin independent of its anticoagulant activity Acta Haematologica Polonica 25(3): 243-251
Millot, F.; Bara, L.; Etienne, J.; Samama, M.; Laruelle, P. 1987: Lipolytic and anticoagulant activities of heparin and one of its low molecular weight derivatives Nouvelle Revue Francaise d'Hematologie 29(6): 397-400
Matsuoka, T.; Inoue, K.; Mizuno, K.; Kita, Y.; Nakanishi, S.; Asai, S.; Taoka, R.; Soda, T.; Terai, A. 2012: Heparin as bridging anticoagulant and antiplatelet therapy during the perioperative period Hinyokika Kiyo. Acta Urologica Japonica 58(5): 223-226
Strukova, S.M.; Khlebnikova, T.G.; Umarova, B.A.; Kulibali, M. 1984: Heparin secretion by mast cells as an index of the status of the anticoagulant system Biulleten' Eksperimental'noi Biologii i Meditsiny 97(2): 131-134
Völker, W.; Böhm, A.; Schmidt, A.; Svahn, C.M.; Gellerbring, A.K.; Mattsson, C.; Ekvärn, S.; Robenek, H.; Buddecke, E. 1995: Inhibition of smooth muscle cell proliferation and neointimal growth by low-anticoagulant heparin Arzneimittel-Forschung 45(5): 546-550
Burg, M.; Ostendorf, T.; Mooney, A.; Koch, K.M.; Floege, J. 1997: Treatment of experimental mesangioproliferative glomerulonephritis with non-anticoagulant heparin: therapeutic efficacy and safety Laboratory Investigation; A Journal of Technical Methods and Pathology 76(4): 505-516
Schneider, T.; Heuer, B.; Deller, A.; Boesken, W.H. 2000: Continuous haemofiltration with r-hirudin (lepirudin) as anticoagulant in a patient with heparin induced thrombocytopenia (HIT II) Wiener Klinische Wochenschrift 112(12): 552-555
Shammas, N.W.; Lemke, J.H.; Dippel, E.J.; McKinney, D.E.; Takes, V.S.; Youngblut, M.; Harris, M.; Harb, C.; Kapalis, M.J.; Holden, J. 2003: In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant Journal of Invasive Cardiology 15(5): 242-246
Harenberg, J.; Stehle, G.; Dempfle, C.E.; von Hodenberg, E.; Heene, D.L. 1989: The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects Folia Haematologica 116(6): 967-980
Pomortseva, I.V.; Ovchinnikova, L.K.; Shcheglova, N.V. 1990: The influence of the Soviet antimalarial preparation dabequin on the hemostatic system and on the anticoagulant effect of heparin Farmakologiia i Toksikologiia 53(1): 59-62
Shah, A.C.; Genoni, M.; Niederhäuser, U.; Maloigne, M.; Turina, M. 2000: R-hirudin (lepirudin, refludan) as an alternative anticoagulant in heparin-induced thrombocytopenia during cardiopulmonary bypass connection Schweizerische Medizinische Wochenschrift 130(23): 896-899
Patel, A.A.; White, C.M.; Coleman, C.I. 2007: Use of protamine to rapidly reverse anticoagulant effect of unfractionated heparin in patients undergoing percutaneous coronary intervention Connecticut Medicine 71(2): 93-95
Ushkalova, E.A.; Kremneva, V.F.; Ovchinnikova, L.K.; Shcheglova, N.V. 1989: Comparative evaluation of the anticoagulant activity of the sodium and calcium salts of heparin, isolated from swine intestinal mucosa Farmakologiia i Toksikologiia 52(3): 51-55